<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-054067</identifier>
<setSpec>0213-0599</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Carbamazepine hipersensivity syndrome during the treatment of bipolar disorder</dc:title>
<dc:description xml:lang="en">Anticonvulsant hypersensitivity syndrome is a rare ;;skin reaction, potentially mortal, characterized by rash, ;;fever, lynphadenopathy and internal organ involvement ;;A case of carbamazepine hypersensitivity syndrome in ;;a diagnosed patient of bipolar disorder is described. The ;;clinical picture appears four weeks after beginning ;;treatment with this drug and it is even developed with ;;an multiorganic affectation and a fluctuating course in ;;the presence of the drug. The clinical diagnosis is confirmed ;;by a patch test positive to carbamazepine. The ;;psychiatrist must inform to the patient and his family, ;;on the possible appearance of the hypersensitivity syndrome, ;;during the first trimester of treatment with carbamazepine, ;;to make an early diagnosis and to diminish ;;the complications and the vital risk. Carbamazepine ;;must retire immediately if rash cutaneous appears in the ;;patient, because not difference of the declared one in the ;;most benign reactions</dc:description>
<dc:creator>Cabero Almarcegui, M</dc:creator>
<dc:creator>Barroso Cañizares, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome de hipersensibilidad a anticonvulsivanteses una reacción dérmica rara, potencialmente mortal,caracterizada por rash, fiebre, linfadenopatía y afectaciónde varios órganos. Se describe un síndrome dehipersensibilidad a carbamazepina en un paciente diagnosticadode trastorno bipolar. El cuadro clínico aparececuatro semanas después de iniciar tratamiento con estefármaco y se desarrolla con afectación multiorgánica yun curso fluctuante, incluso en presencia de la droga. Eldiagnóstico clínico es confirmado por un test del parchepositivo a la carbamazepina. El psiquiatra debe informaral paciente y a su familia sobre la posible aparicióndel síndrome de hipersensibilidad, durante el primer trimestrede tratamiento con carbamazepina, para realizarun diagnóstico precoz y disminuir las complicaciones yel riesgo vital. La carbamazepina debe retirarse inmediatamentecuando aparece un rash cutáneo porque nose diferencia del manifestado en las reacciones másbenignas</dc:description>
<dc:source>An. psiquiatr;23(2): 78-80, mar.-abr. 2007.</dc:source>
<dc:identifier>ibc-054067</dc:identifier>
<dc:title xml:lang="es">Síndrome de hipersensibilidad a carbamazepina durante el tratamiento del trastorno bipolar</dc:title>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d26426</dc:subject>
<dc:subject>^d4404^s22027</dc:subject>
<dc:subject>^d4404^s22016</dc:subject>
<dc:subject>^d22673^s22045</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d934^s22020</dc:subject>
<dc:subject>^d1738^s22057</dc:subject>
<dc:subject>^d2256^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2256^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200703</dc:date>
</metadata>
</record>
</ibecs-document>
